Superimposed Coagulopathic Conditions in Cirrhosis: Infection and Endogenous Heparinoids, Renal Failure, and Endothelial Dysfunction

Clinics in Liver Disease

Volumn 13, Issue 1, 2009, Pages 33-42

  Smalberg, Jasper H ^a   Leebeek, Frank W G ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Organization for Scientific Research   (Netherlands)

Author keywords

Cirrhosis; Endothelial dysfunction; Hemostasis; Heparinoids; Infection; Renal failure

Indexed keywords

ANTIBIOTIC AGENT; DESMOPRESSIN; ENDOTHELIN 1; ERYTHROPOIETIN; ESTROGEN; HEPARINOID; VON WILLEBRAND FACTOR;

BACTERIAL INFECTION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER DISEASE; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PROPHYLAXIS; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HEPARINOIDS; HUMANS; KIDNEY FAILURE; LIVER CIRRHOSIS; VARICOSE VEINS; VON WILLEBRAND FACTOR;

EID: 58149343371     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.09.006     Document Type: Review

References (89)

1. Lisman T., Leebeek F.W., and de Groot P.G. Haemostatic abnormalities in patients with liver disease. J Hepatol 37 2 (2002) 280-287
2. Borzio M., Salerno F., Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 33 1 (2001) 41-48
3. Caly W.R., and Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 18 3 (1993) 353-358
4. Rimola A., Soto R., Bory F., et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 4 1 (1984) 53-58
5. Bernard B., Grange J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29 6 (1999) 1655-1661
6. Bernard B., Cadranel J.F., Valla D., et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 108 6 (1995) 1828-1834
7. Goulis J., Armonis A., Patch D., et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 27 5 (1998) 1207-1212
8. Bleichner G., Boulanger R., Squara P., et al. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg 73 9 (1986) 724-726
9. Hou M.C., Lin H.C., Liu T.T., et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 39 3 (2004) 746-753
10. Jun C.H., Park C.H., Lee W.S., et al. Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. J Korean Med Sci 21 5 (2006) 883-890
11. Thalheimer U., Triantos C.K., Samonakis D.N., et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 54 4 (2005) 556-563
12. Lin R.S., Lee F.Y., Lee S.D., et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 22 2 (1995) 165-172
13. Goulis J., Patch D., and Burroughs A.K. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 353 9147 (1999) 139-142
14. Pinzani M., Milani S., De Franco R., et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110 2 (1996) 534-548
15. Laffi G., Foschi M., Masini E., et al. Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation. Hepatology 22 6 (1995) 1666-1673
16. Radomski M.W., Palmer R.M., and Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2 8567 (1987) 1057-1058
17. Riddell D.R., Graham A., and Owen J.S. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 272 1 (1997) 89-95
18. Gratton J.P., Maurice M.C., and D'Orleans-Juste P. Characterization of endothelin receptors and endothelin-converting enzyme activity in the rabbit lung. J Cardiovasc Pharmacol 26 Suppl 3 (1995) S88-S90
19. Vane J.R., and Botting R.M. Pharmacodynamic profile of prostacyclin. Am J Cardiol 75 3 (1995) 3A-10A
20. Teien A.N. Heparin elimination in patients with liver cirrhosis. Thromb Haemost 38 3 (1977) 701-706
21. Salooja N., and Perry D.J. Thrombelastography. Blood Coagul Fibrinolysis 12 5 (2001) 327-337
22. Chau T.N., Chan Y.W., Patch D., et al. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 43 2 (1998) 267-271
23. Papatheodoridis G.V., Patch D., Webster G.J., et al. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology 29 4 (1999) 1085-1090
24. Montalto P., Vlachogiannakos J., Cox D.J., et al. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 37 4 (2002) 463-470
25. Zambruni A., Thalheimer U., Coppell J., et al. Endogenous heparin-like activity detected by anti-Xa assay in infected cirrhotic and non-cirrhotic patients. Scand J Gastroenterol 39 9 (2004) 830-836
26. Thalheimer U., Triantos C., Samonakis D., et al. Endogenous heparinoids in acute variceal bleeding. Gut 54 2 (2005) 310-311
27. Senzolo M., Coppell J., Cholongitas E., et al. The effects of glycosaminoglycans on coagulation: a thromboelastographic study. Blood Coagul Fibrinolysis 18 3 (2007) 227-236
28. Senzolo M., Cholangitas E., Riddell A., et al. Heparinase I, II and III modified thromboelastography for the detection of different glycosaminoglycans' effect in cirrhotics with bacterial infection. J Hepatol 44 Suppl 2 (2006) S72
29. Arroyo V., Gines P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23 1 (1996) 164-176
30. Noris M., and Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies?. Blood 94 8 (1999) 2569-2574
31. Livio M., Benigni A., and Remuzzi G. Coagulation abnormalities in uremia. Semin Nephrol 5 2 (1985) 82-90
32. Remuzzi G. Bleeding in renal failure. Lancet 1 8596 (1988) 1205-1208
33. Di Minno G., Cerbone A., Usberti M., et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108 3 (1986) 246-252
34. Eknoyan G., and Brown III C.H. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1 1 (1981) 17-23
35. Remuzzi G., Benigni A., Dodesini P., et al. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 71 3 (1983) 762-768
36. Escolar G., Diaz-Ricart M., Cases A., et al. Abnormal cytoskeletal assembly in platelets from uremic patients. Am J Pathol 143 3 (1993) 823-831
37. Castillo R., Lozano T., Escolar G., et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 68 2 (1986) 337-342
38. Benigni A., Boccardo P., Galbusera M., et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 22 5 (1993) 668-676
39. Escolar G., Cases A., Bastida E., et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76 7 (1990) 1336-1340
40. Gawaz M.P., Dobos G., Spath M., et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5 1 (1994) 36-46
41. Sohal A.S., Gangji A.S., Crowther M.A., et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 118 3 (2006) 417-422
42. Weigert A.L., and Schafer A.I. Uremic bleeding: pathogenesis and therapy. Am J Med Sci 316 2 (1998) 94-104
43. Marietta M., Facchinetti F., Neri I., et al. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res 88 2 (1997) 229-235
44. Noris M., Benigni A., Boccardo P., et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 44 2 (1993) 445-450
45. Fernandez F., Goudable C., Sie P., et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 59 1 (1985) 139-148
46. Livio M., Gotti E., Marchesi D., et al. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 2 8306 (1982) 1013-1015
47. Cases A., Escolar G., Reverter J.C., et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 42 3 (1992) 668-672
48. Fabris F., Cordiano I., Randi M.L., et al. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis. Pediatr Nephrol 5 2 (1991) 225-228
49. Moia M., Mannucci P.M., Vizzotto L., et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 2 8570 (1987) 1227-1229
50. Van Geet C., Van Damme-Lombaerts R., Vanrusselt M., et al. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link?. Thromb Haemost 64 1 (1990) 7-10
51. Di Minno G., Martinez J., McKean M.L., et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 79 5 (1985) 552-559
52. Rabiner S.F. The effect of dialysis on platelet function of patients with renal failure. Ann N Y Acad Sci 201 (1972) 234-242
53. Remuzzi G., Livio M., Marchiaro G., et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 22 4-6 (1978) 347-353
54. Stewart J.H., and Castaldi P.A. Uraemic bleeding: a reversible platelet defect corrected by dialysis. Q J Med 36 143 (1967) 409-423
55. Boccardo P., Remuzzi G., and Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 30 5 (2004) 579-589
56. Zwaginga J.J., Ijsseldijk M.J., Beeser-Visser N., et al. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 75 7 (1990) 1498-1508
57. Hedges S.J., Dehoney S.B., Hooper J.S., et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 3 3 (2007) 138-153
58. Casserly L.F., and Dember L.M. Thrombosis in end-stage renal disease. Semin Dial 16 3 (2003) 245-256
59. Escolar G., Diaz-Ricart M., and Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep 4 5 (2005) 359-367
60. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 11 11 (2003) 1278-1289
61. Laffi G., and Marra F. Complications of cirrhosis: is endothelium guilty?. J Hepatol 30 3 (1999) 532-535
62. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105 1A (1998) 32S-39S
63. Racanelli V., and Rehermann B. The liver as an immunological organ. Hepatology 43 2 Suppl 1 (2006) S54-S62
64. Mano T., Masuyama T., Yamamoto K., et al. Endothelial dysfunction in the early stage of atherosclerosis precedes appearance of intimal lesions assessable with intravascular ultrasound. Am Heart J 131 2 (1996) 231-238
65. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
66. Tooke J.E. Microvascular function in human diabetes. A physiological perspective. Diabetes 44 7 (1995) 721-726
67. Bosch J., and Garcia-Pagan J.C. Complications of cirrhosis. I. Portal hypertension. J Hepatol 32 1 Suppl (2000) 141-156
68. Iwakiri Y., and Groszmann R.J. Vascular endothelial dysfunction in cirrhosis. J Hepatol 46 5 (2007) 927-934
69. Bellis L., Berzigotti A., Abraldes J.G., et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 37 2 (2003) 378-384
70. Gupta T.K., Toruner M., Chung M.K., et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 4 (1998) 926-931
71. Rockey D.C., and Chung J.J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114 2 (1998) 344-351
72. Sarela A.I., Mihaimeed F.M., Batten J.J., et al. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 44 5 (1999) 749-753
73. Graupera M., Garcia-Pagan J.C., Pares M., et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 39 4 (2003) 515-521
74. Graupera M., March S., Engel P., et al. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 288 4 (2005) G763-G770
75. Braet F., and Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 1 1 (2002) 1
76. Iwakiri Y., and Groszmann R.J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 2 Suppl 1 (2006) S121-S131
77. Groszmann R.J., and Abraldes J.G. Portal hypertension: from bedside to bench. J Clin Gastroenterol 39 4 Suppl 2 (2005) S125-S130
78. Wiest R., and Groszmann R.J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35 2 (2002) 478-491
79. Deanfield J.E., Halcox J.P., and Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 10 (2007) 1285-1295
80. Vapaatalo H., and Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 7 5 (2001) 1075-1085
81. Vaughan D.E. PAI-1 and atherothrombosis. J Thromb Haemost 3 8 (2005) 1879-1883
82. Leebeek F.W., Kluft C., Knot E.A., et al. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 101 5 (1991) 1382-1390
83. Violi F., Ferro D., Quintarelli C., et al. Clotting abnormalities in chronic liver disease. Dig Dis 10 3 (1992) 162-172
84. Ferro D., Quintarelli C., Lattuada A., et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 23 6 (1996) 1377-1383
85. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 44 1 (2006) 53-61
86. Albornoz L., Alvarez D., Otaso J.C., et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 30 3 (1999) 451-455
87. Bruno C.M., Sciacca C., Cilio D., et al. Circulating adhesion molecules in patients with virus-related chronic diseases of the liver. World J Gastroenterol 11 29 (2005) 4566-4569
88. Giron-Gonzalez J.A., Martinez-Sierra C., Rodriguez-Ramos C., et al. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol 40 2 (2005) 217-224
89. Mallat A., and Lotersztajn S. Multiple hepatic functions of endothelin-1: physiopathological relevance. J Hepatol 25 3 (1996) 405-413